List of works - James R. Brown

Airway host-microbiome interactions in chronic obstructive pulmonary disease.

scientific article published on 6 June 2019

Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.

scientific article

Comparative genomics of Klebsiella pneumoniae strains with different antibiotic resistance profiles

scientific article

Computational biology approaches for selecting host–pathogen drug targets ⬇️

scientific article published on January 28, 2011

Computational biology in anti-tuberculosis drug discovery.

scientific article published on June 2009

Expanding the drug discovery space with predicted metabolite-target interactions

scientific article published on 05 March 2021

Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects

scientific article published on 28 December 2017

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing

scientific article (publication date: 2014)

Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data

scientific article (publication date: 2013)

Human microbial metabolites as a source of new drugs.

scientific article

Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations

scientific article published on 31 January 2018

Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets.

scientific article published on 10 January 2018

Microbiome Metabolite Mimics Accelerate Drug Discovery

scientific article published on 03 April 2020

Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase

scientific article

Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development

scientific article published on 19 April 2013

Modulating the human gut microbiome as an emerging therapeutic paradigm

scientific article published on January 2013

Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease

scientific article published on 27 July 2020

New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.

scientific article

Novel Role for Protein Inhibitor of Activated STAT 4 (PIAS4) in the Restriction of Herpes Simplex Virus 1 by the Cellular Intrinsic Antiviral Immune Response

scientific article published on 02 March 2016

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

scientific article

Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients

scientific article published on 13 December 2019

PICRUSt2 for prediction of metagenome functions

scientific article published on 01 June 2020

Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery ⬇️

scientific article published on 05 January 2011

Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery

scientific article

SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1.

scientific article published on 20 April 2016

Selective Spectrum Antibiotic Modulation of the Gut Microbiome in Obesity and Diabetes Rodent Models

scientific article

Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.

scientific article published on 19 June 2019

Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.

scientific article

T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer

scientific article published on 04 September 2019

Target prediction for an open access set of compounds active against Mycobacterium tuberculosis

scientific article (publication date: 2013)

The Microbiome Factor in Drug Discovery and Development

scientific article published on 23 December 2019

List of works by James R. Brown

Airway host-microbiome interactions in chronic obstructive pulmonary disease.

Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.

Comparative genomics of Klebsiella pneumoniae strains with different antibiotic resistance profiles

Computational biology approaches for selecting host–pathogen drug targets ⬇️

Computational biology in anti-tuberculosis drug discovery.

Expanding the drug discovery space with predicted metabolite-target interactions

Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing

Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data

Human microbial metabolites as a source of new drugs.

Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations

Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets.

Microbiome Metabolite Mimics Accelerate Drug Discovery

Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase

Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development

Modulating the human gut microbiome as an emerging therapeutic paradigm

Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease

New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.

Novel Role for Protein Inhibitor of Activated STAT 4 (PIAS4) in the Restriction of Herpes Simplex Virus 1 by the Cellular Intrinsic Antiviral Immune Response

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients

PICRUSt2 for prediction of metagenome functions

Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery ⬇️

Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery

SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1.

Selective Spectrum Antibiotic Modulation of the Gut Microbiome in Obesity and Diabetes Rodent Models

Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.

Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.

T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer

Target prediction for an open access set of compounds active against Mycobacterium tuberculosis

The Microbiome Factor in Drug Discovery and Development